This is certainly great news for the medical field ------
Patrys has selected a high-performing variant of Deoxymab 3E10, PAT-DX1 as the lead candidate from the program and is progressing PAT-DX1, and its nanoparticle-conjugated form PAT-DX1-NP into pre-clinical cancer models. Patrys believes that PAT-DX1 may have application across a wide range of malignancies such as gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.
If this is not fantastic I don’t know what is.
- Forums
- ASX - By Stock
- PAB
- Ann: PAT-DX1 Conjugated to Nanoparticles, Targets Tumors
Ann: PAT-DX1 Conjugated to Nanoparticles, Targets Tumors, page-17
-
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.001(14.3%) |
Mkt cap ! $14.40M |
Open | High | Low | Value | Volume |
0.7¢ | 0.8¢ | 0.7¢ | $26.93K | 3.669M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 98812 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 4509656 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 98812 | 0.007 |
19 | 2750686 | 0.006 |
10 | 4212443 | 0.005 |
5 | 4174000 | 0.004 |
4 | 2729016 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.008 | 4509656 | 3 |
0.009 | 700000 | 1 |
0.010 | 1161000 | 3 |
0.011 | 1600000 | 3 |
0.012 | 472407 | 3 |
Last trade - 14.25pm 01/07/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online